**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 90081

**Manuscript Type:** EDITORIAL

**Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm**

Tirandi A *et al*. Inflammation in causing AMI in patients with MPNs

Amedeo Tirandi, Elisa Schiavetta, Elia Maioli, Fabrizio Montecucco, Luca Liberale

**Amedeo Tirandi, Elisa Schiavetta, Elia Maioli, Fabrizio Montecucco, Luca Liberale,** Department of Internal Medicine, University of Genoa, Genoa 16132, Italy

**Fabrizio Montecucco, Luca Liberale,** IRCCS Ospedale Policlinico San Martino, Genoa – Italian Cardiovascular Network, Genoa 16132, Italy

**Author contributions:** Tirandi A wrote the paper and drew the image; Schiavetta E, and Maioli E critically revised the paper; Liberale L and Montecucco F supervised the entire work. All the authors read the final version of the manuscript and approve it for the submission and publication.

**Corresponding author: Fabrizio Montecucco, MD, PhD, Full Professor,** Department of Internal Medicine University of Genoa, 6 v.le Benedetto XV, Genoa 16132, Italy. fabrizio.montecucco@unige.it

**Received:** November 22, 2023

**Revised:** January 1, 2024

**Accepted:** January 18, 2024

**Published online:** February 26, 2024

**Abstract**

Myeloproliferative neoplasms (MPN) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. They are clinically classifiable into four main diseases: chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis. These pathologies are closely related to cardio- and cerebrovascular diseases due to the increased risk of arterial thrombosis, the most common underlying cause of acute myocardial infarction. Recent evidence shows that the classical Virchow triad (hypercoagulability, blood stasis, endothelial injury) might offer an explanation for such association. Indeed, patients with MPN might have a higher number and more reactive circulating platelets and leukocytes, a tendency toward blood stasis because of a high number of circulating red blood cells, endothelial injury or overactivation as a consequence of sustained inflammation caused by the neoplastic clonal cell. These abnormal cancer cells, especially when associated with the JAK2V617F mutation, tend to proliferate and secrete several inflammatory cytokines. This sustains a pro-inflammatory state throughout the body. The direct consequence is the induction of a pro-thrombotic state that acts as a determinant in favoring both venous and arterial thrombus formation. Clinically, MPN patients need to be carefully evaluated to be treated not only with cytoreductive treatments but also with cardiovascular protective strategies.

**Key Words:** Inflammation; Myeloproliferative neoplasm; Acute coronary syndrome; Myocardial infarction; Thrombosis; Cancer

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Tirandi A, Schiavetta E, Maioli E, Montecucco F, Liberale L. Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm. *World J Cardiol* 2024; 16(2): 58-63

**URL**: https://www.wjgnet.com/1949-8462/full/v16/i2/58.htm

**DOI**: https://dx.doi.org/10.4330/wjc.v16.i2.58

**Core Tip:** Myeloproliferative neoplasms (MPNs) are a group of three diseases: essential thrombocythemia, polycythemia vera, and primary myelofibrosis. MPNs have a high risk of acute coronary syndromes due to a pro-thrombotic state. This state is induced by abnormal cancer cells that tend to proliferate and secrete several inflammatory cytokines, sustaining a pro-inflammatory state throughout the body. Clinically, MPN patients need to be carefully evaluated for cytoreductive treatments and cardiovascular protective strategies.

**INTRODUCTION**

Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. MPNs are subdivided into four main diseases: Chronic myeloid leukemia, essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis. Thrombosis is one of the most common complications of MPNs, which can occur in both arterial and venous vessels. As such, patients with MPN are at high risk of cardio- and cerebrovascular diseases such as myocardial infarction, deep venous thrombosis, and stroke[1,2]. Epidemiologically, up to 75% of patients with MPNs experience a major adverse cardiovascular event (MACE) as a complication of their clinical condition, and about a third after a first acute coronary syndrome (ACS) have another MACE[3]. Of interest, ACS might precede the development of a clinically overt MPNs[4]. Such higher cardiovascular risk is probably related to the hyper-viscosity and thrombocytosis that are found in these neoplastic conditions. The main key elements that contribute to this pro-thrombotic state are the augmented number of circulating platelets and their hyperactivation, the marked leukocytosis, the Janus kinase 2 (JAK2) mutation, and the inflammatory state that especially concern the endothelium. In addition, the concomitant presence of classic cardiovascular risk factors (such as smoking, dyslipidemia, hypertension, *etc.*) further contributes to the higher risk of possible cardiovascular acute diseases in these patients. In this editorial, we comment on a recent article by Manan *et al*[5] published in the *World Journal of Cardiology* entitled “Acute myocardial infarction in myeloproliferative neoplasms”. We provide the key insights of the paper, re-discussing the main topics focusing on the major mechanism underlying the relation of MPNs and ACS.

**How inflammation in myeloproliferative neoplasms can predispose to acute coronary syndromes**

Inflammation plays a central role in the pathogenesis of cardiac diseases, particularly in the development of atherosclerotic disease[6]. In cases of MPN, the whole body undergoes a persistent inflammatory state, and patients typically suffer from inflammation-mediated symptoms such as fever, night sweats, weight loss, and fatigue[2]. Accordingly, in patients with ET and PV, the presence of high levels of C-reactive protein is associated with a higher risk of thrombosis[7]. Although more information is available concerning the role of inflammation in causing thrombosis, the underlying mechanisms through which MPNs contribute to the development of ACS are not completely understood. The concept is that thrombosis can affect both the arterial and venous vessels in MPN patients, and ACS are mainly caused by an arterial thrombosis of the coronary vessels[8]. The basic principle for the development of a thrombus remains the notorious Virchow triad (hypercoagulability, blood stasis, endothelial injury)[9] (Figure 1).

***Hypercoagulability***

MPNs, especially ET, are associated with increased platelet count as well as their functionality impairment. ET is characterized by an overproduction of platelets from megakaryocytes as these cells become excessively sensitive to thrombopoietin[10]. As such, the risk of thrombosis is particularly higher in these patients. Such cells tend to be larger and more reactive[11]. Further to their increased pro-thrombotic activity, dysfunctional platelets are less sensitive to the inhibitory effect mediated by aspirin or clopidogrel[12]. Recently, the greater reactivity of platelets in MPNs has been related to the higher number of mitochondria within their membrane[13].

Leukocytosis is known to be a non-specific marker of acute myocardial infarction (AMI)[14], where it is thought to reflect the inflammatory response toward myocardial necrosis in AMI patients. In MPNs patients, it can also be an expression of a more aggressive disease or an exaggerated inflammatory response[3]. As such, patients with AMI and marked leukocytosis are associated with a worse prognosis[15,16]. On the other hand, leukocytosis itself is a possible cause of AMI. For instance, acute leukemia patients with marked leukocytosis are known to possibly have acute myocardial infarction as a complication of their clinical condition[16]. In these patients, the presence of a pro-thrombophilic state and higher expression of adhesion molecules (*e.g.*, CD56) are thought to favor the onset of ACS[17]. Similarly, patients with MPNs patients tend to have a pro-thrombotic state, and the presence of more circulating leukocytes can also reflect the presence of more reactive leukocytes with a tendency toward a dysregulated inflammatory response toward the onset of AMI. As such, leukocytosis in patients with PV can be considered as a possible hallmark of a higher cardiovascular risk[18]. Indeed, pro-inflammatory states are known to increase the expression of procoagulants such as tissue factor, fibrinogen and adhesion molecules.

JAK2 is a non-receptor tyrosine kinase in the Janus kinase family. JAK2 mutations are implicated in MPNs, including PV, ET, and myelofibrosis[19]. Furthermore, JAK2 mutation is also associated with a higher risk of ACS[3]. The most prevalent JAK2 mutation in MPNs is called JAK2V617F. This mutation consists of a substitution of a valine with phenylalanine in position 617. The resulting neoplastic clones favor the development of inflammation *via* the secretion of several inflammatory cytokines (*e.g.*, interleukin-1, interleukin-6, tumor necrosis factor-α, interferon-γ), resulting in mesenchymal and endothelial cell activation, bone marrow fibrosis, and eventually ending in acute myeloid leukemia[20]. Furthermore, JAK2V617F is associated with a higher expression of adhesion molecules, especially integrins, resulting in the favoring of thrombus formation[2]. Also, neutrophils harboring such mutations showed a higher tendency to form neutrophil extracellular traps[21-23]. Again, NETosis is known to facilitate thrombus formation working as a scaffold for fibrin and cells as well as carrying different molecules with pro-coagulant activity[24]. The result is a higher risk of thrombotic complications[25]. Other MPN-associated mutations involve genes encoding for reticulum-associated protein calreticulin and thrombopoietin receptor[26]. Of interest such mutations again result in the activation of JAK/STAT signaling and to date inhibitors of JAK2-driven signal have been approved for patients with myelofibrosis and PV[27].

***Blood stasis***

Blood stasis is typically found in MPNs patients. As all MPN relates with the expansion of a clone, and results in increased number of circulating cells a certain degree of blood stasis is expected in all patients with the disease[28]. The higher hematocrit found in PV patients is secondary to the higher number of circulating erythrocytes found in these patients. Such a higher number of circulating red blood cells is associated with blood stasis, blood flow disturbances, and hyper-viscosity[29], therefore favoring the development of thrombosis[30]. Similarly, in patients with ET cell count can hit high at over 1 million abnormal (see above) platelets/mL. Blood stasis together with the presence of over-reactive platelets can probably favor the development of thrombi because of platelet activation, as reported in studies on animal models that showed that platelet adhesion to the endothelium is directly related to the hematocrit levels[31]. Clinically, PV patients are more prone to have vascular complications, such ACS[18].

***Endothelial damage***

The endothelium is a pivotal player in the pathophysiology of arterial thrombosis. Indeed, under physiological conditions endothelial cells exert anti-thrombotic roles by producing several mediators including nitric oxide. The endothelium probably participates in the formation of thrombi as a consequence of the hyper-coagulability state rather than being the primary origin of thrombus formation[32]. However, under the pro-inflammatory pressure lead by the neoplastic clone, endothelial cells get dysfunctionally activated and secrete further pro-inflammatory cytokines propagating inflammation. Activated endothelial cells increase the expression of adhesion molecules including E-selectin on their surfaces in MPN patients[33]. Although E-selectin is not considered a marker of unstable coronary plaque[34], the endothelial overexpression of E-selectin can trigger an excessive leukocyte response in MPN patients. As such, even the smallest plaque tear might favor an exaggerated intracoronary activation of platelets, causing the clinical manifestation of ACS.

Furthermore, endothelial cells with mutated JAK2 have been found in patients carrying the JAK2 V617F mutation[35]. Of interest, such endothelial cells express a proadhesive phenotype with increased P-selectin expression that may be a further link with the increased thrombosis risk[36]. Indeed, therapeutic approaches aiming at P-selectin blockade have shown preclinical potential to reduce thrombosis. Increased atherosclerosis may not be the only link between AMI and MPNs, as almost 20% of AMI in MPNs occurs in patients without significant atherosclerotic occlusive disease[37]. Here, coronary vasoconstriction may play a role. Indeed, JAK2 V617F mice have shown increased arterial vasoconstriction due to their lower levels of nitric oxide, increased oxidative and inflammatory stress[38]. Specifically, erythrocytes-derived microvescicles have been deemed responsible for such phenotype and proteomic analysis of particles derived from JAK2V617F erythrocytes suggested MPO as the potential mediator[38].

**CONCLUSION**

MPNs are associated with cardiovascular diseases, especially those sustained by a thrombotic event. MPNs arise from clonal hematopoiesis of indeterminate potential (CHIP), whose investigation in the last years provided fundamental insight into the causal link between thrombosis and MPNs. CHIP is defined as the presence of a clonal mutation in a driver gene, occurring with a variant burden of ≥ 2% but without any clinical evidence of a hematologic neoplasm. Patients with CHIP show a 10-fold increased risk of developing any hematologic malignancy, including MPNs[39]. Of interest, the magnitude of risk enrichment due to CHIP is even higher than that of classical cardiovascular risk factors[39]. Experimental and clinical observations further point at inflammation as the culprit link between CHIP and cardiovascular disease[40,41]. Indeed, CHIP is nowadays seen as another characteristic of human aging, and it accompanies with another typical features of aging which is the appearance of a chronic low-grade pro-inflammatory state (inflamm-ageing). With recent trails showing the potential for anti-inflammatory therapies in cardiology[42], targeting specific inflammatory mediators may be a way to blunt prothrombotic state of patients with MPN. The role of CHIP and inflamm-ageing in cardiovascular disease development have been recently reviewed[41,43,44].

Manan *et al*[5] reviewed the recent literature and provided insight into the pathogenesis and clinical consequences of the association between hematological and cardiovascular diseases. Further research is needed to establish cardiovascular preventive strategies for MPN patients.

**REFERENCES**

1 **Frederiksen H**, Szépligeti S, Bak M, Ghanima W, Hasselbalch HC, Christiansen CF. Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity. *Clin Epidemiol* 2019; **11**: 955-967 [PMID: 31807079 DOI: 10.2147/CLEP.S216787]

2 **Bhuria V**, Baldauf CK, Schraven B, Fischer T. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved. *Int J Mol Sci* 2022; **23** [PMID: 35328626 DOI: 10.3390/ijms23063206]

3 **Leiva O**, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G. Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms. *Hematol Rep* 2023; **15**: 398-404 [PMID: 37367089 DOI: 10.3390/hematolrep15020040]

4 **Gouri A**, Yakhlef A, Dekaken A, Bentorki AA. Acute myocardial infarction revealing a polycythemia vera. *Ann Biol Clin (Paris)* 2012; **70**: 489-491 [PMID: 22796622 DOI: 10.1684/abc.2012.0735]

5 **Manan MR**, Kipkorir V, Nawaz I, Waithaka MW, Srichawla BS, Găman AM, Diaconu CC, Găman MA. Acute myocardial infarction in myeloproliferative neoplasms. *World J Cardiol* 2023; **15:** 571-581 [PMID: 38058401 DOI: 10.4330/wjc.v15.i11.571]

6 **Tirandi A**, Montecucco F, Liberale L. Heart and vessels 'on fire'. *Eur J Clin Invest* 2023; **53**: e14052 [PMID: 37394695 DOI: 10.1111/eci.14052]

7 **Barbui T**, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. *Haematologica* 2011; **96**: 315-318 [PMID: 21173097 DOI: 10.3324/haematol.2010.031070]

8 **Nurkalem Z**, Uslu N, Gorgulu S, Eren M. Left main coronary thrombosis with essential thrombocythemia. *J Thromb Thrombolysis* 2006; **22**: 165-167 [PMID: 17111201 DOI: 10.1007/s11239-006-9016-5]

9 **Chung I**, Lip GY. Virchow's triad revisited: blood constituents. *Pathophysiol Haemost Thromb* 2003; **33**: 449-454 [PMID: 15692259 DOI: 10.1159/000083844]

10 **Kawasaki H**, Nakano T, Kohdera U, Kobayashi Y. Hypersensitivity of megakaryocyte progenitors to thrombopoietin in essential thrombocythemia. *Am J Hematol* 2001; **68**: 194-197 [PMID: 11754402 DOI: 10.1002/ajh.1178]

11 **Vannucchi AM**, Barbui T. Thrombocytosis and thrombosis. *Hematology Am Soc Hematol Educ Program* **2007:** 363-370 [PMID: 18024652 DOI: 10.1182/asheducation-2007.1.363]

12 **Koupenova M**, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update. *Eur Heart J* 2017; **38**: 785-791 [PMID: 28039338 DOI: 10.1093/eurheartj/ehw550]

13 **Ross DM**, Liang HPH, Iqra Z, Whittaker S, Tan CW, Dale BJ, Chen VM. Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin. *Sci Rep* 2023; **13**: 9172 [PMID: 37280424 DOI: 10.1038/s41598-023-36266-2]

14 **Green SM**, Vowels J, Waterman B, Rothrock SG, Kuniyoshi G. Leukocytosis: a new look at an old marker for acute myocardial infarction. *Acad Emerg Med* 1996; **3**: 1034-1041 [PMID: 8922012 DOI: 10.1111/j.1553-2712.1996.tb03350.x]

15 **Kruk M**, Przyłuski J, Kalińczuk L, Pregowski J, Kadziela J, Kaczmarska E, Petryka J, Kepka C, Klopotowski M, Chmielak Z, Ciszewski A, Demkow M, Karcz M, Witkowski A, Ruzyłło W. Hemoglobin, leukocytosis and clinical outcomes of ST-elevation myocardial infarction treated with primary angioplasty: ANIN Myocardial Infarction Registry. *Circ J* 2009; **73**: 323-329 [PMID: 19106461 DOI: 10.1253/circj.cj-08-0370]

16 **Pesaro AE**, Nicolau JC, Serrano CV Jr, Truffa R, Gaz MV, Karbstein R, Giraldez RR, Kalil Filho R, Ramires JA. Influence of leukocytes and glycemia on the prognosis of patients with acute myocardial infarction. *Arq Bras Cardiol* 2009; **92**: 84-93 [PMID: 19360239 DOI: 10.1590/s0066-782x2009000200003]

17 **Colović N**, Bogdanović A, Virijević M, Vidović A, Tomin D. Acute Myocardial Infarction during Induction Chemotherapy for Acute MLL t(4;11) Leukemia with Lineage Switch and Extreme Leukocytosis. *Srp Arh Celok Lek* 2015; **143**: 734-738 [PMID: 26946771 DOI: 10.2298/sarh1512734c]

18 **Landolfi R**, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. *Blood* 2007; **109**: 2446-2452 [PMID: 17105814 DOI: 10.1182/blood-2006-08-042515]

19 **Kralovics R**, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med* 2005; **352**: 1779-1790 [PMID: 15858187 DOI: 10.1056/NEJMoa051113]

20 **Lussana F**, Rambaldi A. Inflammation and myeloproliferative neoplasms. *J Autoimmun* 2017; **85**: 58-63 [PMID: 28669446 DOI: 10.1016/j.jaut.2017.06.010]

21 **Wolach O**, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Sci Transl Med* 2018; **10** [PMID: 29643232 DOI: 10.1126/scitranslmed.aan8292]

22 **Bonaventura A**, Montecucco F, Dallegri F, Carbone F, Lüscher TF, Camici GG, Liberale L. Novel findings in neutrophil biology and their impact on cardiovascular disease. *Cardiovasc Res* 2019; **115**: 1266-1285 [PMID: 30918936 DOI: 10.1093/cvr/cvz084]

23 **Bonaventura A**, Liberale L, Carbone F, Vecchié A, Diaz-Cañestro C, Camici GG, Montecucco F, Dallegri F. The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases. *Thromb Haemost* 2018; **118**: 6-27 [PMID: 29304522 DOI: 10.1160/TH17-09-0630]

24 **Liberale L**, Holy EW, Akhmedov A, Bonetti NR, Nietlispach F, Matter CM, Mach F, Montecucco F, Beer JH, Paneni F, Ruschitzka F, Libby P, Lüscher TF, Camici GG. Interleukin-1β Mediates Arterial Thrombus Formation *via* NET-Associated Tissue Factor. *J Clin Med* 2019; **8** [PMID: 31779200 DOI: 10.3390/jcm8122072]

25 **Scott LM**. The JAK2 exon 12 mutations: a comprehensive review. *Am J Hematol* 2011; **86**: 668-676 [PMID: 21674578 DOI: 10.1002/ajh.22063]

26 **Vainchenker W**, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. *Blood* 2017; **129**: 667-679 [PMID: 28028029 DOI: 10.1182/blood-2016-10-695940]

27 **Shawky AM**, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A Comprehensive Overview of Globally Approved JAK Inhibitors. *Pharmaceutics* 2022; **14** [PMID: 35631587 DOI: 10.3390/pharmaceutics14051001]

28 **Hasselbalch HC**, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. *Blood* 2021; **137**: 2152-2160 [PMID: 33649757 DOI: 10.1182/blood.2020008109]

29 **Willerslev A**, Hansen MM, Klefter ON, Bjerrum OW, Hasselbalch HC, Clemmensen SN, Larsen M, Munch IC. Non-invasive imaging of retinal blood flow in myeloproliferative neoplasms. *Acta Ophthalmol* 2017; **95**: 146-152 [PMID: 27682603 DOI: 10.1111/aos.13249]

30 **Pearson TC**, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. *Lancet* 1978; **2**: 1219-1222 [PMID: 82733 DOI: 10.1016/s0140-6736(78)92098-6]

31 **Turitto VT**, Weiss HJ. Red blood cells: their dual role in thrombus formation. *Science* 1980; **207**: 541-543 [PMID: 7352265 DOI: 10.1126/science.7352265]

32 **Friedenberg WR**, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. *Am J Hematol* 1992; **40**: 283-289 [PMID: 1503083 DOI: 10.1002/ajh.2830400408]

33 **Musolino C**, Alonci A, Allegra A, Spatari G, Bellomo G, Tringali O, Quartarone C, Squadrito G, Quartarone M. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications. *Am J Hematol* 1998; **57**: 109-112 [PMID: 9462541 DOI: 10.1002/(sici)1096-8652(199802)57:2<109::aid-ajh3>3.0.co;2-#]

34 **Galvani M**, Ferrini D, Ottani F, Nanni C, Ramberti A, Amboni P, Iamele L, Vernocchi A, Nicolini FA. Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease. *J Thromb Thrombolysis* 2000; **9**: 53-60 [PMID: 10590190 DOI: 10.1023/a:1018656530541]

35 **Guy A**, Gourdou-Latyszenok V, Le Lay N, Peghaire C, Kilani B, Dias JV, Duplaa C, Renault MA, Denis C, Villeval JL, Boulaftali Y, Jandrot-Perrus M, Couffinhal T, James C. Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. *Haematologica* 2019; **104**: 70-81 [PMID: 30171023 DOI: 10.3324/haematol.2018.195321]

36 **Guadall A**, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. *Thromb Haemost* 2018; **118**: 1586-1599 [PMID: 30103245 DOI: 10.1055/s-0038-1667015]

37 **Pósfai É**, Marton I, Borbényi Z, Nemes A. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. *Anatol J Cardiol* 2016; **16**: 397-402 [PMID: 27182615 DOI: 10.14744/AnatolJCardiol.2015.6125]

38 **Poisson J**, Tanguy M, Davy H, Camara F, El Mdawar MB, Kheloufi M, Dagher T, Devue C, Lasselin J, Plessier A, Merchant S, Blanc-Brude O, Souyri M, Mougenot N, Dingli F, Loew D, Hatem SN, James C, Villeval JL, Boulanger CM, Rautou PE. Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. *J Clin Invest* 2020; **130**: 2630-2643 [PMID: 32045382 DOI: 10.1172/JCI124566]

39 **Jaiswal S**, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014; **371**: 2488-2498 [PMID: 25426837 DOI: 10.1056/NEJMoa1408617]

40 **Fuster JJ**, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andrés V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science* 2017; **355**: 842-847 [PMID: 28104796 DOI: 10.1126/science.aag1381]

41 **Libby P**, Ebert BL. CHIP (Clonal Hematopoiesis of Indeterminate Potential): Potent and Newly Recognized Contributor to Cardiovascular Risk. *Circulation* 2018; **138**: 666-668 [PMID: 30359133 DOI: 10.1161/CIRCULATIONAHA.118.034392]

42 **Liberale L**, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. *Cardiovasc Res* 2021; **117**: 411-422 [PMID: 32666079 DOI: 10.1093/cvr/cvaa211]

43 **Liberale L**, Montecucco F, Tardif JC, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. *Eur Heart J* 2020; **41**: 2974-2982 [PMID: 32006431 DOI: 10.1093/eurheartj/ehz961]

44 **Liberale L**, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week. *J Am Coll Cardiol* 2022; **79**: 837-847 [PMID: 35210039 DOI: 10.1016/j.jacc.2021.12.017]

**Footnotes**

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 22, 2023

**First decision:** December 23, 2023

**Article in press:** January 18, 2024

**Specialty type:** Cardiac & cardiovascular systems

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chen K, China **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Zhang YL

**Figure Legends**



**Figure 1 Myeloproliferative diseases in predisposing to acute coronary syndrome: The Virchow triad.** Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by the clonal proliferation of hematopoietic progenitor or stem cells. Patients with MPN are at high risk of cardiovascular events, especially those sustained by arterial thrombosis. Different causal links have been recently shown to account for increased acute myocardial infarction risk in patients with MPNs. ACS: Acute coronary syndrome; MPNs: Myeloproliferative neoplasms.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**